High virologic response rate at End of Treatment (EOT) following triple therapy of previously untreated HCV Genotype 1 (G1) infection with boceprevir in German real-life
P Buggisch, H Löhr, G Teuber, H Steffens, M Kraus, C John, P Geyer, B Weber, T Witthoeft, A Herrmann, M Hoesl, U Naumann, T Dahhan, D Hartmann, B Dreher, M Bilzer · Zeitschrift für Gastroenterologie · 2014 · Heft 08
Bibliografische Angaben
Zusammenfassung
Background: Triple therapy with the HCV protease inhibitor boceprevir has been approved as new standard of care for patients with chronic HCV G1 infection. The NOVUS observational study was conducted to investigate the efficacy of this novel antiviral therapy in German real-life. Methods: From April 2012 until January 2014, 536 patients with G1 infection were recruited in the ongoing NOVUS study by 97 practices and hospitals in Germany. Patients were treated with pegylated interferons (PegIFN) and ribavirin (RBV) together with boceprevir for 24 to 44 weeks after a 4 weeks lead-in period with PegIFN/RBV according…
